AIMS/HYPOTHESIS: Proliferative diabetic retinopathy results from excess blood vessel growth into the vitreous fluid of the eye. Retinal angiogenesis is regulated by expression of vascular endothelial growth factor (VEGF), and many studies have shown that VEGF is critically involved in proliferative diabetic retinopathy. VEGF is alternatively spliced to form the angiogenic (VEGF(xxx)) and potentially anti-angiogenic (VEGF(xxx)b) family of isoforms. The VEGF(xxx)b family is found in normal tissues, but down-regulated in renal and prostate cancer. Previous studies on endogenous expression of VEGF in the eye have not distinguished between the two families of isoforms. METHODS: We measured VEGF(xxx)b isoform expression in normal human eye tissue (lens, sclera, retina and iris) and vitreous fluid using enzyme-linked immunosorbent assay and Western blotting with a VEGF(xxx)b-specific antibody. RESULTS: VEGF(xxx)b protein was expressed in lens, sclera, retina, iris and vitreous fluid. Multiple isoforms were seen, including VEGF(165)b, VEGF(121)b, VEGF(145)b, VEGF(183)b and VEGF(189)b. In non-diabetic patients, 64+/-7% of the VEGF in the vitreous was VEGF(xxx)b (n=18), whereas in diabetic patients only 12.5+/-3.6% of total VEGF was VEGF(xxx)b. CONCLUSIONS/ INTERPRETATION: Since VEGF(xxx)b inhibits VEGF(xxx)-induced angiogenesis in a one-to-one stoichiometric manner, these results show that in the eye of diabetic patients VEGF splicing was switched from an anti-angiogenic to a pro-angiogenic environment. This occurred through changes to the ratio of VEGF(xxx):VEGF(xxx)b. Alterations to splicing, and through that to the balance of VEGF isoforms, could therefore be a potential therapeutic strategy for diabetic retinopathy.
AIMS/HYPOTHESIS: Proliferative diabetic retinopathy results from excess blood vessel growth into the vitreous fluid of the eye. Retinal angiogenesis is regulated by expression of vascular endothelial growth factor (VEGF), and many studies have shown that VEGF is critically involved in proliferative diabetic retinopathy. VEGF is alternatively spliced to form the angiogenic (VEGF(xxx)) and potentially anti-angiogenic (VEGF(xxx)b) family of isoforms. The VEGF(xxx)b family is found in normal tissues, but down-regulated in renal and prostate cancer. Previous studies on endogenous expression of VEGF in the eye have not distinguished between the two families of isoforms. METHODS: We measured VEGF(xxx)b isoform expression in normal human eye tissue (lens, sclera, retina and iris) and vitreous fluid using enzyme-linked immunosorbent assay and Western blotting with a VEGF(xxx)b-specific antibody. RESULTS:VEGF(xxx)b protein was expressed in lens, sclera, retina, iris and vitreous fluid. Multiple isoforms were seen, including VEGF(165)b, VEGF(121)b, VEGF(145)b, VEGF(183)b and VEGF(189)b. In non-diabeticpatients, 64+/-7% of the VEGF in the vitreous was VEGF(xxx)b (n=18), whereas in diabeticpatients only 12.5+/-3.6% of total VEGF was VEGF(xxx)b. CONCLUSIONS/ INTERPRETATION: Since VEGF(xxx)b inhibits VEGF(xxx)-induced angiogenesis in a one-to-one stoichiometric manner, these results show that in the eye of diabeticpatientsVEGF splicing was switched from an anti-angiogenic to a pro-angiogenic environment. This occurred through changes to the ratio of VEGF(xxx):VEGF(xxx)b. Alterations to splicing, and through that to the balance of VEGF isoforms, could therefore be a potential therapeutic strategy for diabetic retinopathy.
Authors: Jeanette Woolard; Wen-Ying Wang; Heather S Bevan; Yan Qiu; Lucia Morbidelli; Rowan O Pritchard-Jones; Tai-Gen Cui; Marto Sugiono; Elizabeth Waine; Rachel Perrin; Rebecca Foster; Jonathon Digby-Bell; Jacqueline D Shields; Cheryl E Whittles; Rosey E Mushens; David A Gillatt; Marina Ziche; Steven J Harper; David O Bates Journal: Cancer Res Date: 2004-11-01 Impact factor: 12.701
Authors: Evangelos S Gragoudas; Anthony P Adamis; Emmett T Cunningham; Matthew Feinsod; David R Guyer Journal: N Engl J Med Date: 2004-12-30 Impact factor: 91.245
Authors: L P Aiello; E A Pierce; E D Foley; H Takagi; H Chen; L Riddle; N Ferrara; G L King; L E Smith Journal: Proc Natl Acad Sci U S A Date: 1995-11-07 Impact factor: 11.205
Authors: José Pedro De La Cruz; José Antonio González-Correa; Ana Guerrero; Felipe Sánchez de la Cuesta Journal: Diabetes Metab Res Rev Date: 2004 Mar-Apr Impact factor: 4.876
Authors: Michelle M Baltes-Breitwisch; Robin A Artac; Rebecca C Bott; Renee M McFee; Jill G Kerl; Debra T Clopton; Andrea S Cupp Journal: Reproduction Date: 2010-05-10 Impact factor: 3.906
Authors: Takayuki Baba; D Scott McLeod; Malia M Edwards; Carol Merges; Tanusree Sen; Debasish Sinha; Gerard A Lutty Journal: Dev Dyn Date: 2012-01-31 Impact factor: 3.780
Authors: Robin A Artac; Renee M McFee; Robyn A Longfellow Smith; Michelle M Baltes-Breitwisch; Debra T Clopton; Andrea S Cupp Journal: Biol Reprod Date: 2009-07-15 Impact factor: 4.285
Authors: E S Rennel; A H R Varey; A J Churchill; E R Wheatley; L Stewart; S Mather; D O Bates; S J Harper Journal: Br J Cancer Date: 2009-08-25 Impact factor: 7.640
Authors: Victoria L Bills; Julia Varet; Ann Millar; Steven J Harper; Peter W Soothill; David O Bates Journal: Clin Sci (Lond) Date: 2009-02 Impact factor: 6.124